SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 5, 2003

 

AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)

 

Oregon

 

0-22613

 

93-0797222

(State or other jurisdiction of
incorporation or organization)

 

(Commission File Number)

 

(IRS Employer
Identification Number)

 

 

 

 

 

One S.W. Columbia, Suite 1105
Portland, OR 97258

(Address of principal executive offices)

 

 

 

 

 

(503) 227-0554

Registrant’s telephone number, including area code

 

 



 

Item 12. Results of Operation and Financial Condition.

 

AVI BioPharma, Inc. (the “Company”) issued a press release on August 5, 2003, before the opening of trading in its Common Stock on the Nasdaq National Market System, a copy of which is attached as Exhibit 99.1.

 

The Press Release announces Second Quarter Financial Results and updates the Company’s product research and clinical trials.

 

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

 

None

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on August 8, 2003.

 

 

AVI BioPharma, Inc.

 

 

 

 

By:

/s/ ALAN P. TIMMINS

 

 

 

Alan P. Timmins

 

 

President and Chief Operating Officer

 

 

(Principal Operating Officer)

 

2